首页 > 文献资料
-
From April 1992 to April 1998, 104 cases of chemotherapy-induced leukopenia were treated by injection into Zusanli (ST 36) with a mixture consisting of dexamethasone, 654-2, ATP and inosine. The therapeutic results were satisfactory as reported in the following.Clinical Data In this series, all the 127 cases were definitely diagnosed by pathological examination. Of them, 93 were male and 34 female, ranging in age from 12 to 75 years. 38 cases were carcinoma of esophagus, 22 carcinoma of cardia of stomach, 21 cancer of lung, 11 hepatic carcinoma, 8 lymphoma, 8 mammary cancer, 7 carcinoma of colon, and 12 other kinds of the tumors. Leukocyte count was below 4.0×109/L in all the patients after being treated by chemotherapy.
-
浅谈乳腺癌围手术期的健康教育
乳腺癌是妇女常见的恶性肿瘤之一.发病率相当高,占女性恶性肿瘤的第2位,发病年龄有向年轻化发展的趋势.目前治疗乳腺癌的原则是早期发现、早期诊断、早期治疗.治疗的有效方法是手术切除加术后化学治疗或放射治疗.现将近几年我科乳腺癌病人围手术期护理及健康教育介绍如下.
-
晚期乳腺癌的介入治疗及护理
晚期乳腺癌是指临床Ⅲ期癌,常因原发癌灶体积过大而丧失手术机会,治疗效果差.我院从1998年始,对26例晚期乳腺癌病人行术前介入治疗,使病人获得Ⅱ期手术机会,效果满意.
-
乳腺癌C-erbB-2基因蛋白测定的临床应用价值探讨
原癌基因C-erbB-2又称HER-2/neu,位于人的第17号染色体的q11-q12位.C-erbB-2基因蛋白在人类许多恶性肿瘤中存在过度表达.自1987年Slamon报道了C-erbB-2基因与乳腺癌有关,在乳腺癌领域里研究多的是C-erbB-2与乳腺癌的关系.我们对我院1987~1993年收治的147例乳腺癌患者病理腊块标本经用PAP免疫组织化学法测定C-erbB-2后,按测定的结果(过度表达为阳性,非过度表达为阴性)把临床病例资料分成C-erbB-2(+)及C-erbB-2(-)两组,全组资料进行随访,研究C-erbB-2临床预后意义,分析其与影响乳腺癌预后诸因素的关系,探讨C-erbB-2测定的临床应用价值.
-
非常规分割放疗乳腺癌转移性癌痛的疗效
Objective To investigate therapeutic effect of rapidly divided radiotherapy in the management of pain due to bone metastases in mammary cancer. Method 20 patients among 33 received rapidly divided radiotherapy in 25 lesions, DTU-5CTY a time, 2~ 3 times a week, total dose was 15~ 30 Gy. 13 patients (22 lesions ) received routine dividing radiotherapy, DT 4~ 5 Gy each time, 5 times a week, total dose was 40~ 60 Gy. Result In rapidly divided group, total analgesic rate was 95.0% (19/20). In routine dividing group, total analgesic rate was 69.3% . There was no significant difference between the 2 groups (P >0.05). Pain was controlled in 84% of lesions in rapidly divided group 2 week after radiotherapy. Analgesic rate of DT 20~ 30 Gy went up to 45.5% . Differences between 2 groups were significant statistically (P< 0.01).Conclusion Rapidly divided radiotherapy is rapid and reliable in managing pain. Patients can endure its toxicological and adverse reactions . It's therapeutic effect is comparable with that of routine divided radiotherapy.
-
妊娠晚期合并乳腺癌行剖宫产术加乳癌根治术患者的围手术期护理
乳腺癌是人类常见的一种恶性肿瘤,也是女性主要恶性肿瘤之一,妊娠期乳腺癌是一种特殊类型的乳腺癌,妊娠晚期合并乳腺癌在临床上实属少见.我科1999年1月-2006年1月对10例妊娠晚期合并乳腺癌患者行剖宫产术加乳癌根治术效果满意,现报道如下.
-
注重乳腺癌的综合治疗
1乳腺癌综合治疗的必要性乳腺癌一旦确诊,尽早手术,彻底切除,就能根治,这是长期以来人们一直认为、乃至今日有些医生也将其视为是治疗乳腺癌不可动摇的原则.当今来看,这一提法不但片面,有时是错误的.
-
乳癌术后辅助内分泌治疗的新思路
内分泌治疗是乳癌主要治疗手段之一,其历史可追溯到1896年,英国学者Beatson采用卵巢切除术治疗绝经前晚期乳癌;二十世纪70年代,三苯氧胺(TAM)的问世成为乳癌内分泌药物治疗的里程碑;90年代,新一代芳香化酶抑制剂的问世,则使乳癌内分泌治疗进入一个新时代.
-
乳腺癌的治疗现状及进展
乳腺癌的发病率在欧洲、北美、澳大利亚和许多拉丁美洲国家居女性恶性肿瘤的首位,占女性恶性肿瘤的20%~30%.在我国,预计到2003年底,乳腺癌的发病率将上升到36±/10万人,从流行病学发展趋势看,乳腺癌越来越集中在大城市(北京、上海、天津等),跃居女性恶性肿瘤的首位.
-
血管内皮生长因子(VEGF)在乳腺癌中的研究进展
肿瘤的生长和转移需要新生血管的形成[1],而血管的形成又受多种相关因子的调节,血管内皮生长因子(vascular endothelial growth factor,VEGF)又称血管渗透因子(vascular permeability factor,VPF)就是其中重要的因子之一.
-
1例炎性乳癌延误诊断的教训
1临床资料患者,女,31岁.左侧乳腺肿块伴腋窝淋巴结肿大半年余.
-
男性小细胞乳腺癌1例报告
男,40岁,4个月前无诱因出现左侧胸壁肿胀,曾诊断为"男性乳腺发育症",服中药治疗无效,因左侧胸壁肿胀进行性增大2个月而就诊.查体:左侧乳晕上方皮肤隆起,皮肤表面未见异常,皮温正常,皮下可触及13 cm×12 cm大小肿块,基底广泛,质硬,与胸壁固定,轻压痛,左侧腋下及锁骨上区淋巴结未触及.